Ambuja Cements (AMBUJACEM) — Board Meeting

📢 Key Event
Board approved Q2 FY2026 results and multiple amalgamation schemes.

🔄 What Changed
Recognized 113 Crore exceptional item reversal and 223 Crore incentive write-down.

🔮 What's Next
NCLT-directed shareholder meeting scheduled for Scheme 2 on September 28, 2026.

💡 Investor Takeaway
Exceptional item reversals improved net profitability despite flat revenue growth.

Ambuja Cements approved unaudited Q2 FY2026 results showing ₹6,563 crore total income, [amount context mismatch] crore PAT, and [amount context mismatch] crore comprehensive income. The Board reviewed exceptional items including 113 Crore tax settlement reversal, 223 Crore incentive write-down, and 90 Crore stamp duty provision. Amalgamation schemes with Adani Cementation and others received regulatory nods, while US DOJ charges against a director remain pending. No material misstatements were found in the financials.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AMBUJACEM ✨ Ask AI About This

About Ambuja Cements Limited (AMBUJACEM)

Construction Materials · Cement & Cement Products · Listed on NSE

Market Cap: ₹1,07,215.34 Cr P/E: 23.3 ROE: 7.7% ROCE: 4.6%

View full AMBUJACEM stock details →

📡 Get AI alerts when AMBUJACEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AMBUJACEM — Free

💡 Ask AI about this filing

"When will Scheme 2 shareholder approval be finalized?" "What is the expected impact of US DOJ charges on governance?" "How will the 223 Crore incentive write-down affect future cash flows?"

Ask AI Free →

📊 More AMBUJACEM filings

See all AMBUJACEM filings →

🔥 Also filed on 28 July 2026

LT Larsen & Toubro Limited Corporate Action TI Tilaknagar Industries Limited Financial Results LGBBROSLTD LG Balakrishnan & Bros Limited Announcement MAXIND Max India Limited Annual Report RVNL Rail Vikas Nigam Limited Corporate Action NIRAJ Niraj Cement Structurals Limited Offer Document

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AMBUJACEM files new disclosures

Track AMBUJACEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.